Does glucuretic therapy with the novel SGLT2 inhibitor empagliflozin at a dose of 25mg once daily significantly increase the odds of achieving an HbA1c target of <7% compared to placebo in adults suffering from diabetes mellitus type II?
Does glucuretic therapy with the novel SGLT2 inhibitor empagliflozin at a dose of 25mg once daily significantly increase the odds of achieving an HbA1c target of <7% compared to placebo in adults suffering from diabetes mellitus type II? This is…